NCT03903562View on ClinicalTrials.gov

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,990

Participants

Timeline

Start Date

April 27, 2019

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions

Papillomavirus Infections

Interventions

BIOLOGICAL

V503

0.5 mL 9vHPV VLP Vaccine

Trial Locations (2)

312030

Shaoxing keqiao center for disease prevention and control ( Site 0001), Shaoxing

324300

Kaihua country Center for Disease Control and Prevention ( Site 0002), Quzhou

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03903562 - Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) | Biotech Hunter | Biotech Hunter